XNW29016 / Evopoint - LARVOL DELTA

A Phase I/II Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of XNW29016 Tablets in Advanced Solid Tumors With Failed Standard Treatment (clinicaltrials.gov) - P1/2 | N=132 | Recruiting | Sponsor: Evopoint Biosciences Inc.

New P1/2 trial • Solid Tumor

Discovery of XNW29016, a PARG inhibitor for HRD cancer therapy (AACR 2025) - "SNU601 and HCC1806 cells with acquired niraparib resistance or carboplatin resistance continued to be sensitive to XNW29016, but insensitive to niraparib. In toxicological studies, XNW29016 exhibits satisfactory safety profile. Altogether, these preclinical findings warrant further clinical evaluation of XNW29016 in patients with HRD cancers."

Breast Cancer • Gastric Cancer • Oncology • Ovarian Cancer • Solid Tumor